|
|
|
Insider
Information: |
Orbimed Genesis Gp Llc |
Relationship: |
Director, 10% Owner |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
14 |
|
Direct
Shares |
0 |
|
Indirect Shares
|
39,972,594 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$413,975,295 |
|
|
Total
Shares |
39,972,594 |
|
|
Total
Value |
$413,975,295 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
|
|
Stock
price went down : |
|
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Keros Therapeutics, Inc. |
KROS |
Director |
2020-04-13 |
0 |
2024-08-13 |
119,522 |
Premium* |
|
Scpharmaceuticals Inc. |
SCPH |
10% Owner |
2020-05-21 |
0 |
2024-08-13 |
252,858 |
Premium* |
|
Logicbio Therapeutics, Inc. |
LOGC |
Director, 10% Owner |
2020-10-01 |
0 |
2020-10-01 |
296,296 |
Premium* |
|
Galecto Inc. |
GLTO |
Director, 10% Owner |
2020-11-02 |
0 |
2020-11-02 |
1,031,811 |
Premium* |
|
Edgewise Therapeutics, Inc. |
EWTX |
Director, 10% Owner |
|
0 |
2024-01-23 |
14,756,096 |
Premium* |
|
Ikena Oncology, Inc. |
IKNA |
Director |
2021-03-30 |
0 |
2023-08-04 |
7,928,543 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
Director |
2021-09-17 |
0 |
2024-05-18 |
0 |
Premium* |
|
Theseus Pharmaceuticals, Inc. |
THRX |
Director, 10% Owner |
2021-10-12 |
0 |
2024-02-14 |
0 |
Premium* |
|
Janux Therapeutics, Inc. |
JANX |
Director |
2021-12-16 |
0 |
2021-12-29 |
231,098 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
Director, 10% Owner |
2022-01-26 |
0 |
2022-01-26 |
226,704 |
Premium* |
|
Pmv Pharmaceuticals, Inc. |
PMVP |
10% Owner |
2022-05-26 |
0 |
2023-11-22 |
6,475,291 |
Premium* |
|
Terns Pharmaceuticals, Inc. |
TERN |
Director, 10% Owner |
2022-08-16 |
0 |
2024-07-16 |
755,635 |
Premium* |
|
Disc Medicine, Inc |
IRON |
Director |
2023-12-18 |
0 |
2024-06-17 |
235,391 |
Premium* |
|
Enliven Therapeutics Ord Shs |
ELVN |
Director, 10% Owner |
2023-02-23 |
0 |
2024-05-16 |
7,663,349 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
SCPH |
Scpharmaceuticals Inc. |
10% Owner |
|
2024-08-13 |
4 |
B |
$4.00 |
$2,000,000 |
I/I |
500,000 |
252,858 |
1.5 |
- |
|
KROS |
Keros Therapeutics, Inc. |
Director |
|
2024-08-13 |
4 |
S |
$44.01 |
$11,002,500 |
I/I |
(250,000) |
119,522 |
0 |
- |
|
TERN |
Terns Pharmaceuticals, In... |
Director |
|
2024-07-16 |
4 |
S |
$10.00 |
$51,880 |
I/I |
(5,188) |
755,635 |
0 |
% |
|
TERN |
Terns Pharmaceuticals, In... |
Director |
|
2024-07-15 |
4 |
S |
$10.00 |
$509,760 |
I/I |
(50,976) |
756,258 |
0 |
% |
|
IRON |
Disc Medicine, Inc |
Director |
|
2024-06-17 |
4 |
B |
$36.00 |
$3,000,024 |
I/I |
83,334 |
235,391 |
2.1 |
% |
|
ALPN |
Alpine Immune Sciences In... |
Director |
|
2024-05-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,680,496) |
0 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
Director |
|
2024-05-16 |
4 |
S |
$22.14 |
$22,877,262 |
I/I |
(1,033,300) |
7,663,349 |
0 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2024-02-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(17,713,600) |
0 |
0 |
- |
|
EWTX |
Edgewise Therapeutics, In... |
Director |
|
2024-01-23 |
4 |
B |
$11.00 |
$4,999,995 |
I/I |
454,545 |
14,436,497 |
2.25 |
% |
|
ALPN |
Alpine Immune Sciences In... |
Director |
|
2024-01-11 |
4 |
OE |
$12.74 |
$1,850,498 |
I/I |
145,251 |
2,416,181 |
0 |
- |
|
ALPN |
Alpine Immune Sciences In... |
Director |
|
2023-12-28 |
4 |
S |
$18.32 |
$25,049,034 |
I/I |
(1,364,849) |
264,315 |
0 |
% |
|
ALPN |
Alpine Immune Sciences In... |
Director |
|
2023-12-27 |
4 |
S |
$19.96 |
$3,622,700 |
I/I |
(181,498) |
406,609 |
0 |
% |
|
IRON |
Disc Medicine, Inc |
Director |
|
2023-12-18 |
4 |
S |
$59.24 |
$102,130 |
D/D |
(1,724) |
0 |
0 |
% |
|
IRON |
Disc Medicine, Inc |
Director |
|
2023-12-18 |
4 |
OE |
$38.00 |
$65,512 |
D/D |
1,724 |
1,724 |
0 |
- |
|
IRON |
Disc Medicine, Inc |
Director |
|
2023-12-14 |
4 |
S |
$56.75 |
$24,584,100 |
I/I |
(433,200) |
224,405 |
0 |
% |
|
IRON |
Disc Medicine, Inc |
Director |
|
2023-12-14 |
4 |
S |
$57.73 |
$11,546 |
I/I |
(200) |
727,807 |
0 |
% |
|
IRON |
Disc Medicine, Inc |
Director |
|
2023-12-13 |
4 |
S |
$58.56 |
$6,248,352 |
I/I |
(106,700) |
281,505 |
0 |
% |
|
IRON |
Disc Medicine, Inc |
Director |
|
2023-12-12 |
4 |
S |
$60.16 |
$1,642,368 |
I/I |
(27,300) |
295,605 |
0 |
% |
|
PMVP |
Pmv Pharmaceuticals, Inc. |
10% Owner |
|
2023-11-22 |
4 |
S |
$2.23 |
$195,763 |
I/I |
(87,786) |
0 |
0 |
- |
|
IKNA |
Ikena Oncology, Inc. |
Director |
|
2023-08-04 |
4/A |
A |
$0.00 |
$0 |
I/I |
153,121 |
5,582,144 |
0 |
- |
|
IKNA |
Ikena Oncology, Inc. |
Director |
|
2023-08-04 |
4 |
A |
$0.00 |
$0 |
I/I |
153,121 |
2,251,218 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
Director |
|
2023-05-17 |
4 |
OE |
$4.28 |
$9,095 |
I/I |
2,125 |
8,663,349 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2023-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
7,899,572 |
288,114 |
0 |
- |
|
IRON |
Disc Medicine, Inc |
Director |
|
2023-02-15 |
4 |
B |
$23.00 |
$2,500,008 |
I/I |
108,696 |
299,205 |
2.25 |
% |
|
IRON |
Disc Medicine, Inc |
Director |
|
2022-12-29 |
4 |
A |
$0.00 |
$0 |
I/I |
2,160,941 |
1,139,507 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|